KRYS

Krystal Biotech, Inc.

172.84 USD
-0.16 (-0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Krystal Biotech, Inc. stock is up 5.1% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 June’s closed higher than May. In the last 8 Unusual Options Trades, there were 6 CALLs, 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Apr 19:50 17 Jan, 2025 100.00 CALL 6 3
02 May 15:55 17 May, 2024 160.00 CALL 25 31
08 May 13:56 17 May, 2024 175.00 CALL 1575 1630
28 May 15:54 19 Jul, 2024 150.00 PUT 59 2
10 Jun 13:53 19 Jul, 2024 195.00 CALL 675 0
10 Jun 17:50 19 Jul, 2024 195.00 CALL 335 0
12 Jun 18:13 21 Jun, 2024 180.00 CALL 38 260
13 Jun 17:46 15 Nov, 2024 160.00 PUT 31 2

About Krystal Biotech, Inc.

Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.